Skip to content
Bored Studies
RecruitingPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Novartis Pharmaceuticals · NCT06846281

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 40–70 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
400
US sites recruiting
44
Study start
June 23, 2025
Record last updated
October 26, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

Being studied: Remibrutinib oral treatment; Ocrelizumab

Conditions: Relapsing Multiple Sclerosis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Male or female aged 40 to 70 years (inclusive)
  • Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
  • Treated with ocrelizumab according to routine clinical practice and at standard dose
  • Neurologically stable within 30 days
  • Suitable to be switched to remibrutinib based on physician judgement or patient preference

Key Exclusion Criteria

  • Diagnosis of primary progressive multiple sclerosis (PPMS) according to the revised 2017 McDonald criteria
  • History of clinically significant Central Nervous System disease or neurological disorders
  • History of confirmed Progressive Multifocal Leukoencephalopathy or neurological symptoms consistent
  • Active clinically significant systemic bacterial, viral, parasitic or fungal infections
  • Active, chronic disease of the immune system other than MS
  • Severe cardiac disease or significant findings on the ECG
  • Participant who is unable to undergo MRI scans
  • History of life-threatening infusion or injection reaction related to ocrelizumab
  • Participants not adequately controlled on ocrelizumab (CD19+ B-cell count ≥10 cells/µL at screening)

Other inclusion and exclusion criteria may apply

Recruiting US locations

  • Perseverance Research Center

    Scottsdale, AZ 85253

    Site contact: Adriana Romero · aromero@prcresearcheducation.com

  • University of California Irvine

    Irvine, CA 92697

    Site contact: Veronica Martin · vero@hs.uci.edu

  • Medstar Washington Hospital Center

    Washington D.C., DC 20010-2975

    Site contact: Anu Bhooshan · +1 202 877 8946 · anu.r.bhooshan@medstar.net

  • Neurology of Central FL Res Ctr

    Altamonte Springs, FL 32714

    Site contact: Adiana Perez · +1 407 790 4990 · adiresearchcfl@gmail.com

  • University of Florida

    Gainesville, FL 32610

    Site contact: Whitney Miller · wjm1433@ufl.edu

  • Memorial Healthcare System

    Hollywood, FL 33021

    Site contact: Hina Khan · +1 954 265 6934 · hikhan@mhs.net

  • Neurology Associates PA

    Maitland, FL 32751

    Site contact: Nicole Perovic · +1 407 647 5996 · nicole.naparesearch@gmail.com

  • Elite Clinical Research

    Miami, FL 33144

    Site contact: Rebeca Fernandez · +1 305 262 3396 · rfernandez@eliteclinicalresearch.com

  • Aqualane Clinical Research

    Naples, FL 34105

    Site contact: Taylor Kerskie · +1 239 434 0332 · taylor@aqualaneresearch.com

  • Advent Health Orlando

    Orlando, FL 32803

    Site contact: McKinzie McTyeire · +1 407 303 5600 · mckinzie.mctyeire@adventhealth.com

  • Orlando Health Clinical Trials

    Orlando, FL 32806

    Site contact: Charlene Carlo · +1 407 352 5434 · Charlene.carlo@orlandohealth.com

  • Tallahassee Neurological Clinic

    Tallahassee, FL 32308

    Site contact: Sharon Devore · +1 850 878 8121 · sharondevore@hotmail.com

  • University Of South Florida

    Tampa, FL 33612

    Site contact: Amber McPherson · +1 813 974 9423 · amjackson@usf.edu

  • Vero Beach Neurology

    Vero Beach, FL 32960

    Site contact: Clellia Bergamino · +1 772 492 7051#232 · cbergamino@geodysseyrsch.com

  • Rush University Medical Center

    Chicago, IL 60607

    Site contact: Bartosz Jacher · Bartosz.Jacher@Northwestern.edu

  • University of Chicago

    Chicago, IL 60637

    Site contact: Cheryl Bibbs · +1 773 702 5382 · cbibbs@bsd.uchicago.edu

  • University of Kansas Hospital

    Kansas City, KS 66160

    Site contact: Vonda Whitley · +1 913 588 9600 · vwhitley@kumc.edu

  • MedStar Montgomery Medical Center

    Olney, MD 20832

    Site contact: Yemisrach Tadesse · yemisrach.g.tadesse@medstar.net

  • Lahey Hospital and Medical Center

    Burlington, MA 01805

    Site contact: Anish Panda · +1 781 744 3874 · Anish.Panda@lahey.org

  • Neurology Center of New England PC

    Foxborough, MA 02035

    Site contact: Jillian Pellegrini · +1 781 551 5812 · jpellegrini@neurocenterne.com

  • Michigan Institute of Neurological

    Farmington Hills, MI 48334

    Site contact: Emily Blazejewski · +1 248 553 0010 · eblazejewski@mindonline.com

  • Memorial HC Ins for Neuroscience

    Owosso, MI 48867

    Site contact: Samantha Katt · skatt@memorialhealthcare.org

  • WA Uni School Of Med

    St Louis, MO 63110

    Site contact: Kiontay Watson · +1 314 362 3293 · k.watson@wustl.edu

  • Cleveland Clinic Foundation

    Las Vegas, NV 89106

    Site contact: Laurinda Keelen · +1 702 483 6003 · keelenl@ccf.org

  • Holy Name Medical Center

    Teaneck, NJ 07666

    Site contact: Diome Kramer · dkramer@holyname.org

  • University of New Mexico

    Albuquerque, NM 87131-0001

    Site contact: Emily Reese · +1 505 272 2836 · ejreese@salud.unm.edu

  • SUNY Buffalo The Jacobs Neuro Inst

    Buffalo, NY 14203

    Site contact: Kara Patrick · kpatrick@buffalo.edu

  • University of North Carolina

    Chapel Hill, NC 27517

    Site contact: Marleny Nolasco · nolascom@neurology.unc.edu

  • Velocity Clinical Research

    Raleigh, NC 27607

    Site contact: Harsh Patel · HPatel@velocityclinical.com

  • Sanford Health

    Fargo, ND 58102

    Site contact: Neurology Research Coordinator · 701-234-2474 · clinicalresearch@sanfordhealth.org

  • Premier Health

    Centerville, OH 45459

    Site contact: Don McHone · djmchone@premierhealth.com

  • Univ of Cincinnati Medical Center

    Cincinnati, OH 45219

    Site contact: Gideon Gyebi · + 1 513 558 4489 · gyebign@ucmail.uc.edu

  • Cleveland Clinic Foundation

    Cleveland, OH 44195

    Site contact: Dawn Maniawski · +1 216 445 5788 · maniawd@ccf.org

  • Ohio Health Research Institute

    Columbus, OH 43214

    Site contact: Megan Heckathorn · 1 614 566 1262 · Megan.Heckathorn@ohiohealth.com

  • Providence Neurological Services West

    Portland, OR 97225

    Site contact: Hunter Weaver · +1 503 216 1150 · hunter.weaver@providence.org

  • Premier Neurology

    Greenville, SC 29605

    Site contact: Anna Lares · +1 864 655 4005 · anna.l@premier-neuro.com

  • Sibyl Wray MD Neurology PC

    Knoxville, TN 37922

    Site contact: Kim Puccio · +1 865 218 6222 · kpuccio@hopeneuro.com

  • Austin Regional Clinic

    Austin, TX 78731

    Site contact: Katerina Rodriguez · +1 512 344 0362 · krodriguez@innovoresearch.com

  • Univ of Texas Southwest Med Center

    Dallas, TX 75390-9034

    Site contact: Manuel Huichapa · manuel.huichapa@utsouthwestern.edu

  • John Peter Smith Hospital

    Fort Worth, TX 76104

    Site contact: Valentina Jovic · +1 817 702 1680 · Vjovic@jpshealth.org

  • Saturn Research Solutions LLC

    Plano, TX 75024

    Site contact: Maxine Fligg · +1 972 403 8184 · mfligg@saturnclinical.com

  • Virginia Commonwealth University

    Richmond, VA 23298-0111

    Site contact: Aarati Pokharel · aarati.pokharel@vcuhealth.org

  • Center for Neurological Disorders G

    Greenfield, WI 53228-1321

    Site contact: Emily Barraza · Emily.barraza@cndmilwaukee.com

  • Medical College of Wisconsin

    Milwaukee, WI 53226

    Site contact: Anna Freiberg · +1 414 805 5249 · afreiberg@mcw.edu

Study contacts (from the official record)

  • Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
  • Novartis Pharmaceuticals · +41613241111
All neurology studies in Arizona →
Efficacy and Safety of Remibrutinib After Switching From… (NCT06846281) | Bored Studies